{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T19:42:37Z","timestamp":1790710957797,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003197","name":"Agenzia Italiana del Farmaco, Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003197","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.yebeh.2021.107989","type":"journal-article","created":{"date-parts":[[2021,5,1]],"date-time":"2021-05-01T11:45:59Z","timestamp":1619869559000},"page":"107989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Pediatric adverse reactions to antiseizure medications \u2013 An analysis of data from the Italian spontaneous reporting system (2001\u20132019)"],"prefix":"10.1016","volume":"119","author":[{"given":"Valentina","family":"Franco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Antonietta","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola Maria","family":"Cutroneo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0882-7865","authenticated-orcid":false,"given":"Ignazio","family":"Arena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-8679","authenticated-orcid":false,"given":"Giuseppe","family":"Cicala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasquale","family":"Marchione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2509-7449","authenticated-orcid":false,"given":"Edoardo","family":"Spina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8703-223X","authenticated-orcid":false,"given":"Emilio","family":"Perucca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1-2","key":"10.1016\/j.yebeh.2021.107989_b0005","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/epi4.3","article-title":"Not all that glitters is gold: a guide to the critical interpretation of drug trials in epilepsy","volume":"1","author":"Perucca","year":"2016","journal-title":"Epilepsia Open"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107989_b0010","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2042098611401129","article-title":"Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources","volume":"2","author":"Loke","year":"2011","journal-title":"Ther Adv Drug Saf"},{"issue":"6","key":"10.1016\/j.yebeh.2021.107989_b0015","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.therap.2019.09.004","article-title":"Pharmacovigilance - The next chapter","volume":"74","author":"Moore","year":"2019","journal-title":"Therapie"},{"issue":"6","key":"10.1016\/j.yebeh.2021.107989_b0020","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1365-2125.2005.02445.x","article-title":"How children's responses to drugs differ from adults","volume":"59","author":"Stephenson","year":"2005","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.yebeh.2021.107989_b0025","unstructured":"Food and Drug Administration. Pediatric Research Equity Act. https:\/\/www.fda.gov\/drugs\/development-resources\/pediatric-research-equity-act-prea. Accessed June 18, 2020."},{"issue":"2","key":"10.1016\/j.yebeh.2021.107989_b0030","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.prrv.2007.04.004","article-title":"The European Regulation on medicines for paediatric use","volume":"8","author":"Dunne","year":"2007","journal-title":"Paediatr Respir Rev"},{"issue":"3","key":"10.1016\/j.yebeh.2021.107989_b0035","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1111\/bcp.12540","article-title":"Paediatric prescribing: why children are not small adults","volume":"79","author":"Ferro","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"10.1016\/j.yebeh.2021.107989_b0040","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/adc.2009.165902","article-title":"A systematic review of safety monitoring and drug toxicity in published randomised controlled trials of antiepileptic drugs in children over a 10-year period","volume":"95","author":"Anderson","year":"2010","journal-title":"Arch Dis Child"},{"issue":"10","key":"10.1016\/j.yebeh.2021.107989_b0045","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40263-014-0189-8","article-title":"Off-label prescribing of antiepileptic drugs in pharmacoresistant epilepsy: a cross-sectional drug utilization study of tertiary care centers in Italy","volume":"28","author":"Franco","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.yebeh.2021.107989_b0050","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/11319100-000000000-00000","article-title":"Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007","volume":"33","author":"Aagaard","year":"2010","journal-title":"Drug Saf"},{"issue":"9","key":"10.1016\/j.yebeh.2021.107989_b0055","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1007\/s00228-012-1255-0","article-title":"Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009","volume":"68","author":"Aldea","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.yebeh.2021.107989_b0060","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s40272-014-0076-2","article-title":"Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: Implications for pharmacovigilance","volume":"16","author":"Blake","year":"2014","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.yebeh.2021.107989_b0065","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1517\/14740338.2014.939581","article-title":"Pediatric drug safety surveillance in Italian pharmacovigilance network: an overview of adverse drug reactions in the years 2001\u20132012","volume":"13","author":"Ferrajolo","year":"2014","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107989_b0070","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1002\/pds.4734","article-title":"Paediatric safety signals identified in VigiBase: methods and results from Uppsala Monitoring Centre","volume":"28","author":"Star","year":"2019","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107989_b0075","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1528-1157.1996.tb00506.x","article-title":"Incidence of epilepsy in childhood and adolescence: a population-based study in Nova Scotia from 1977 to 1985","volume":"37","author":"Camfield","year":"1996","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107989_b0080","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/pds.2269","article-title":"Safety aspects of antiepileptic drugs\u2014focus on pharmacovigilance","volume":"21","author":"Landmark","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.yebeh.2021.107989_b0085","unstructured":"Directive 2001\/83\/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use. https:\/\/www.aifa.gov.it\/documents\/20142\/808717\/2001_83_cons_20081230_en.pdf\/0fbba192-1971-404a-9960-b6216a631f92 Accessed June 14, 2020."},{"key":"10.1016\/j.yebeh.2021.107989_b0090","unstructured":"Regulation (EU) No 1235\/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726\/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394\/2007 on advanced therapy medicinal products. https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2010:348:0001: 0016:EN:PDF Accessed June 14, 2020."},{"issue":"2","key":"10.1016\/j.yebeh.2021.107989_b0095","doi-asserted-by":"crossref","first-page":"109","DOI":"10.2165\/00002018-199920020-00002","article-title":"The medical dictionary for regulatory activities (MedDRA)","volume":"20","author":"Brown","year":"1999","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.yebeh.2021.107989_b0100","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2125.2002.t01-3-01689.x","article-title":"Adverse drug reactions and off-label drug use in paediatric outpatients","volume":"54","author":"Horen","year":"2002","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107989_b0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/pds.1679","article-title":"Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003\u20132007","volume":"18","author":"Johann-Liang","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9971","key":"10.1016\/j.yebeh.2021.107989_b0110","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0140-6736(14)60456-6","article-title":"Epilepsy: new advances","volume":"385","author":"Mosh\u00e9","year":"2015","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107989_b0115","doi-asserted-by":"crossref","first-page":"226","DOI":"10.5694\/mja17.00951","article-title":"The management of epilepsy in children and adults","volume":"208","author":"Perucca","year":"2018","journal-title":"Med J Aust"},{"key":"10.1016\/j.yebeh.2021.107989_b0120","doi-asserted-by":"crossref","unstructured":"Anderson M, Egunsola O, Cherrill J, Millward C, Apostolos Fakis A, Choonara I. A prospective study of adverse drug reactions to antiepileptic drugs in children. BMJ Open 2015;5(6):e008298. doi: 10.1136\/bmjopen-2015-008298.","DOI":"10.1136\/bmjopen-2015-008298"},{"issue":"9","key":"10.1016\/j.yebeh.2021.107989_b0125","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.107989_b0130","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.seizure.2019.07.015","article-title":"Rashes and other hypersensitivity reactions associated with antiepileptic drugs: a review of current literature","volume":"71","author":"Mani","year":"2019","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.yebeh.2021.107989_b0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00228-006-0236-6","article-title":"Use and safety profile of antiepileptic drugs in Italy","volume":"63","author":"Iorio","year":"2007","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.yebeh.2021.107989_b0140","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1111\/epi.12028","article-title":"Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy: initial monotherapy outcomes at 12 months","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.107989_b0145","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.eplepsyres.2019.04.001","article-title":"Efficacy and safety of levetiracetam as adjunctive treatment in children with focal onset seizures: a systematic review and meta-analysis","volume":"153","author":"Cao","year":"2019","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.yebeh.2021.107989_b0150","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1017\/S0012162206000843","article-title":"Aggravation of epilepsy by anti-epileptic drugs","volume":"48","author":"Gayatri","year":"2006","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.yebeh.2021.107989_b0155","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1097\/WNF.0b013e3181646cf2","article-title":"Electrophysiological study in 2 children with transient hypohidrosis induced by topiramate","volume":"31","author":"Margari","year":"2008","journal-title":"Clin Neuropharmacol"},{"issue":"26","key":"10.1016\/j.yebeh.2021.107989_b0160","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.lfs.2007.04.018","article-title":"Topiramate reduced sweat secretion and aquaporin-5 expression in sweat glands of mice","volume":"80","author":"Ma","year":"2007","journal-title":"Life Sci"},{"issue":"2","key":"10.1016\/j.yebeh.2021.107989_b0165","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1684\/epd.2013.0568","article-title":"Hypohidrosis induced by topiramate in an adult patient","volume":"15","author":"Karachristianou","year":"2013","journal-title":"Epileptic Disord"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021002237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:38:47Z","timestamp":1761503927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021002237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":33,"alternative-id":["S1525505021002237"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107989","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pediatric adverse reactions to antiseizure medications \u2013 An analysis of data from the Italian spontaneous reporting system (2001\u20132019)","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.107989","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107989"}}